XASXNSB
Market cap3mUSD
Dec 20, Last price
0.03AUD
Name
NeuroScientific Biopharmaceuticals Ltd
Chart & Performance
P/E
15.16
P/S
—
EPS
0.00
Div Yield, %
0.00%
Shrs. gr., 5y
15.10%
Rev. gr., 5y
18.92%
Revenues
0k
-100.00%
Net income
324k
P
CFO
44k
P
Earnings
Feb 25, 2025
Profile
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | 4,953 | ||||||||
Cost of revenue | 584 | 5,112 | 8,198 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (584) | (159) | (8,198) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (2,212) | (4,953) | (5) | ||||||
Tax Rate | |||||||||
NOPAT | 1,628 | 4,794 | (8,198) | ||||||
Net income | 324 -130.34% | (1,069) -89.76% | (10,435) 228.38% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (4,954) | (4,912) | (7,216) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 44 | (2,304) | (6,942) | ||||||
CAPEX | (2) | (4) | |||||||
Cash from investing activities | (2) | (4) | |||||||
Cash from financing activities | |||||||||
FCF | 1,626 | 4,802 | (8,145) | ||||||
| Balance | |||||||||
Cash | 4,954 | 4,912 | 7,216 | ||||||
Long term investments | |||||||||
Excess cash | 4,954 | 4,664 | 7,216 | ||||||
Stockholders' equity | 5,350 | 4,694 | 5,520 | ||||||
Invested Capital | 396 | 30 | |||||||
ROIC | 764.76% | 16,133.43% | |||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 144,509 | 143,472 | 143,472 | ||||||
Price | 0.04 -50.00% | 0.08 -55.56% | 0.18 -46.27% | ||||||
Market cap | 5,780 -49.64% | 11,478 -55.56% | 25,825 -46.27% | ||||||
EV | 826 | 6,566 | 18,609 | ||||||
EBITDA | (584) | (101) | (8,133) | ||||||
EV/EBITDA | |||||||||
Interest | 5 | ||||||||
Interest/NOPBT | |||||||||